About US
Contact us
>>Back
Merck plots FDA app as sleep drug aces new trial
- Publisher：
- Publication：2012/6/14
Armed with new Phase III data on its potential sleep drug suvorexant, Merck ($MRK) plans to ask FDA to approve the new product later this year. One big selling point: 90% of patients didn't feel sleepy the next day.